Abstract
Background: Intra-tumoral macrophages have been involved as important players in the pathogenesis and progression of cancer. Recently, inflammatory parameters of the systemic inflammatory response have also been proposed as usefully prognostic biomarkers. One of these, the lymphocyte to monocyte ratio (LMR) in peripheral blood has been shown as a prognostic factor in hematologic and some solid tumors. In this study we analyzed for the first time the prognostic value of LMR in a large middle European cohort of pancreatic cancer (PC) patients.
Methods: Data from 474 consecutive patients with ductal adenocarcinoma of the pancreas were evaluated retrospectively. Cancer-specific survival (CSS) was analyzed using the Kaplan-Meier method. To further evaluate the prognostic significance of the LMR, univariate and multivariate Cox regression models were calculated.
Results: Increased LMR at diagnosis was significantly associated with well-established prognostic factors, including high tumor stage and tumor grade (p<0.05). In univariate analysis, we observed that an increased LMR was a significant factor for better CSS in PC patients (HR 0.70; 95% CI 0.57–0.85; p<0.001). In multivariate analysis including age, Karnofsky Index, tumor grade, tumor stage, administration of chemotherapy, LMR and surgical resection, we confirmed increased LMR as an independent prognostic factor for CSS (HR 0.81; 95% CI 0.66–0.99; p=0.04).
Conclusions: In conclusion, we identified LMR as an independent prognostic factor in PC patients. Our results indicate that the LMR might represent a novel and useful marker for patient stratification in PC management.
References
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.10.3322/caac.20138Search in Google Scholar
2. Sharma C, Eltawil KM, Renfrew PD, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990–2010. World J Gastroenterol 2011;17:867–97.10.3748/wjg.v17.i7.867Search in Google Scholar
3. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer 1995;76:1671–7.10.1002/1097-0142(19951101)76:9<1671::AID-CNCR2820760926>3.0.CO;2-RSearch in Google Scholar
4. Kothari N, Saif MW, Kim R. First-line treatment for advanced pancreatic cancer. JOP 2013;14:129–32.Search in Google Scholar
5. Saif MW. Advancements in the management of pancreatic cancer: 2013. JOP 2013;14:112–8.Search in Google Scholar
6. Tinchon C, Hubmann E, Pichler A, Keil F, Pichler M, Rabl H, et al. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta Oncol 2013;52:1231–3.10.3109/0284186X.2013.771821Search in Google Scholar
7. Heinemann V, Haas M, Boeck S. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol 2013;24:2484–92.10.1093/annonc/mdt239Search in Google Scholar
8. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007;246:52–60.10.1097/01.sla.0000259391.84304.2bSearch in Google Scholar
9. Stotz M, Eisner F, Szkandera J, Absenger G, Kornprat P, Lackner C, et al. Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series. J Clin Pathol 2013;66:753–7.10.1136/jclinpath-2012-201394Search in Google Scholar
10. Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Samonigg H, et al. Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients. Br J Cancer 2013;109:2316–22.10.1038/bjc.2013.595Search in Google Scholar
11. Dalpiaz O, Ehrlich GC, Mannweiler S, Hernandez JM, Gerger A, Stojakovic T, et al. Validation of pretreatment neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. Br J Urol Int 2013;114:334–9.10.1111/bju.12441Search in Google Scholar
12. Pichler M, Hutterer GC, Stojakovic T, Mannweiler S, Pummer K, Zigeuner R. High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients. Br J Cancer 2013;109:1123–9.10.1038/bjc.2013.443Search in Google Scholar
13. Absenger G, Szkandera J, Pichler M, Stotz M, Arminger F, Weissmueller M, et al. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 2013;109:395–400.10.1038/bjc.2013.346Search in Google Scholar PubMed PubMed Central
14. Szkandera J, Pichler M, Liegl-Atzwanger B, Absenger G, Stotz M, Ploner F, et al. The elevated pre-operative plasma fibrinogen level is an independent negative prognostic factor for cancer-specific, disease-free and overall survival in soft-tissue sarcoma patients. J Surg Oncol [Epub ahead of print 2013 Oct 7]. doi: 10.1002/jso.23458.10.1002/jso.23458Search in Google Scholar PubMed
15. Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma. Haematologica 2012;97:262–9.10.3324/haematol.2011.050138Search in Google Scholar PubMed PubMed Central
16. Li ZM, Huang JJ, Xia Y, Sun J, Huang Y, Wang Y, et al. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One 2012;7:e41658.10.1371/journal.pone.0041658Search in Google Scholar PubMed PubMed Central
17. Wei X, Huang F, Wei Y, Jing H, Xie M, Hao X, et al. Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma. Leuk Res 2014;38:694–8.10.1016/j.leukres.2014.03.013Search in Google Scholar PubMed
18. Markovic O, Popovic L, Marisavljevic D, Jovanovic D, Filipovic B, Stanisavljevic D, et al. Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma. Eur J Intern Med 2014;25:296–302.10.1016/j.ejim.2014.01.019Search in Google Scholar PubMed
19. Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, et al. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma [Epub ahead of print 2014 Mar 19]. doi: 10.3109/10428194.2014.893313.10.3109/10428194.2014.893313Search in Google Scholar PubMed
20. Yan-Li L, Kang-Sheng G, Yue-Yin P, Yang J, Zhi-Min Z. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leuk Res 2014;38:323–8.10.1016/j.leukres.2013.12.005Search in Google Scholar PubMed
21. Watanabe R, Tomita N, Itabashi M, Ishibashi D, Yamamoto E, Koyama S et al. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Eur J Haematol 2014;92:204–10.10.1111/ejh.12221Search in Google Scholar PubMed
22. Kumagai S, Tashima M, Fujikawa J, Iwasaki M, Iwamoto Y, Sueki Y, et al. Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma. Int J Hematol 2014;99:732–42.10.1007/s12185-014-1576-0Search in Google Scholar PubMed
23. Shin SJ, Roh J, Kim M, Jung MJ, Koh YW, Park CS, et al. Prognostic significance of absolute lymphocyte count/absolute monocyte count ratio at diagnosis in patients with multiple myeloma. Korean J Pathol 2013;47:526–33.10.4132/KoreanJPathol.2013.47.6.526Search in Google Scholar PubMed PubMed Central
24. Koh YW, Park CS, Yoon DH, Suh C, Huh J. Should the cut-off values of the lymphocyte to monocyte ratio for prediction of prognosis in diffuse large B-cell lymphoma be changed in elderly patients? Eur J Haematol 2014;93:340–8.10.1111/ejh.12354Search in Google Scholar PubMed
25. Li J, Jiang R, Liu WS, Liu Q, Xu M, Feng QS, et al. A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma. PLoS One 2013;8:e83069.10.1371/journal.pone.0083069Search in Google Scholar PubMed PubMed Central
26. Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer 2014;110:435–40.10.1038/bjc.2013.785Search in Google Scholar PubMed PubMed Central
27. Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J, et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer 2014;135:362–70.10.1002/ijc.28677Search in Google Scholar PubMed
28. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466–74.10.1200/JCO.2009.23.3452Search in Google Scholar PubMed
29. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 2013;109:416–21.10.1038/bjc.2013.332Search in Google Scholar PubMed PubMed Central
30. Zikos TA, Donnenberg AD, Landreneau RJ, Luketich JD, Donnenberg VS. Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer. Cancer Immunol Immunother 2011;60:819–27.10.1007/s00262-011-0996-4Search in Google Scholar PubMed PubMed Central
31. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380–4.10.1038/35077246Search in Google Scholar PubMed
32. Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002;8:2553–62.Search in Google Scholar
33. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436–44.10.1038/nature07205Search in Google Scholar PubMed
34. Hutterer GC, Pichler M, Chromecki TF, Strini KA, Klatte T, Pummer K, et al. Tumour-associated macrophages might represent a favourable prognostic indicator in patients with papillary renal cell carcinoma. Histopathology 2013;63:309–15.10.1111/his.12163Search in Google Scholar PubMed
35. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196:254–65.10.1002/path.1027Search in Google Scholar PubMed
36. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71–8.10.1038/nrc1256Search in Google Scholar PubMed
37. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263–6.10.1016/j.cell.2006.01.007Search in Google Scholar PubMed
38. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol 2009;9:259–70.10.1038/nri2528Search in Google Scholar PubMed PubMed Central
39. Mroczko B, Groblewska M, Wereszczynska-Siemiatkowska U, Okulczyk B, Kedra B, Laszewicz W, et al. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta 2007;380:208–12.10.1016/j.cca.2007.02.037Search in Google Scholar PubMed
40. Evani SJ, Prabhu RG, Gnanaruban V, Finol EA, Ramasubramanian AK. Monocytes mediate metastatic breast tumor cell adhesion to endothelium under flow. FASEB J 2013;27:3017–29.10.1096/fj.12-224824Search in Google Scholar PubMed PubMed Central
41. Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, et al. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 2006;66:11432–40.10.1158/0008-5472.CAN-06-1867Search in Google Scholar PubMed
42. Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated macrophages and neutrophils in cancer. Immunobiology 2013;218:1402–10.10.1016/j.imbio.2013.06.003Search in Google Scholar PubMed
43. Yang Y, Qin J, Lan L, Li N, Wang C, He P, et al. M-CSF cooperating with NF-kB induces macrophage transformation from M1 to M2 by up-regulating c-Jun. Cancer Biol Ther 2013;15:99–107.10.4161/cbt.26718Search in Google Scholar PubMed PubMed Central
44. Partecke LI, Gunther C, Hagemann S, Jacobi C, Merkel M, Sendler M, et al. Induction of M2-macrophages by tumour cells and tumour growth promotion by M2-macrophages: a quid pro quo in pancreatic cancer. Pancreatology 2013;13:508–16.10.1016/j.pan.2013.06.010Search in Google Scholar PubMed
45. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006;66:11238–46.10.1158/0008-5472.CAN-06-1278Search in Google Scholar PubMed
46. Jetten N, Verbruggen S, Gijbels MJ, Post MJ, De Winther MP, Donners MM. Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo. Angiogenesis 2014;17:109–18.10.1007/s10456-013-9381-6Search in Google Scholar PubMed
47. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA 2008;105:652–6.10.1073/pnas.0708594105Search in Google Scholar PubMed PubMed Central
48. Weizman N, Krelin Y, Shabtay-Orbach A, Amit M, Binenbaum Y, Wong RJ, et al. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene 2014;33:3812–9.10.1038/onc.2013.357Search in Google Scholar PubMed
49. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, et al. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leuk 2013;13:15–8.10.1016/j.clml.2012.09.009Search in Google Scholar PubMed PubMed Central
50. Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol 2012;157:321–30.10.1111/j.1365-2141.2012.09067.xSearch in Google Scholar PubMed
51. Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist 2014;19:266–74.10.1634/theoncologist.2013-0273Search in Google Scholar PubMed PubMed Central
52. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691–703.10.1056/NEJMoa1304369Search in Google Scholar PubMed PubMed Central
53. Alonzo TA. Standards for reporting prognostic tumor marker studies. J Clin Oncol 2005;23:9053–4.10.1200/JCO.2005.04.3778Search in Google Scholar PubMed
54. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067–72.10.1200/JCO.2004.01.0454Search in Google Scholar PubMed
©2015 by De Gruyter
